AU2012217836B2 - Humanized M-CSF mice - Google Patents

Humanized M-CSF mice Download PDF

Info

Publication number
AU2012217836B2
AU2012217836B2 AU2012217836A AU2012217836A AU2012217836B2 AU 2012217836 B2 AU2012217836 B2 AU 2012217836B2 AU 2012217836 A AU2012217836 A AU 2012217836A AU 2012217836 A AU2012217836 A AU 2012217836A AU 2012217836 B2 AU2012217836 B2 AU 2012217836B2
Authority
AU
Australia
Prior art keywords
mouse
csf
human
cells
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012217836A
Other languages
English (en)
Other versions
AU2012217836A1 (en
Inventor
Elizabeth Eynon
Richard Flavell
Markus Manz
Andrew J. Murphy
Chozhavendan RATHINAM
Sean Stevens
George D. Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Yale University
Regeneron Pharmaceuticals Inc
Original Assignee
Institute for Research in Biomedicine IRB
Yale University
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB, Yale University, Regeneron Pharmaceuticals Inc filed Critical Institute for Research in Biomedicine IRB
Publication of AU2012217836A1 publication Critical patent/AU2012217836A1/en
Application granted granted Critical
Publication of AU2012217836B2 publication Critical patent/AU2012217836B2/en
Priority to AU2015202020A priority Critical patent/AU2015202020B2/en
Priority to AU2016259284A priority patent/AU2016259284B2/en
Priority to AU2018213980A priority patent/AU2018213980B2/en
Priority to AU2020210210A priority patent/AU2020210210A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8536—Animal models for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
AU2012217836A 2011-02-15 2012-02-14 Humanized M-CSF mice Active AU2012217836B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2015202020A AU2015202020B2 (en) 2011-02-15 2015-04-21 Humanized M-CSF mice
AU2016259284A AU2016259284B2 (en) 2011-02-15 2016-11-14 Humanized M-CSF mice
AU2018213980A AU2018213980B2 (en) 2011-02-15 2018-08-06 Humanized M-CSF mice
AU2020210210A AU2020210210A1 (en) 2011-02-15 2020-07-29 Humanized M-CSF mice

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161442946P 2011-02-15 2011-02-15
US61/442,946 2011-02-15
PCT/US2012/025040 WO2012112544A2 (en) 2011-02-15 2012-02-14 Humanized m-csf mice

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015202020A Division AU2015202020B2 (en) 2011-02-15 2015-04-21 Humanized M-CSF mice

Publications (2)

Publication Number Publication Date
AU2012217836A1 AU2012217836A1 (en) 2013-03-28
AU2012217836B2 true AU2012217836B2 (en) 2015-01-29

Family

ID=46673120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012217836A Active AU2012217836B2 (en) 2011-02-15 2012-02-14 Humanized M-CSF mice

Country Status (17)

Country Link
US (5) US8847004B2 (enExample)
EP (3) EP2675271B1 (enExample)
JP (5) JP5834097B2 (enExample)
KR (6) KR102585058B1 (enExample)
CN (3) CN105861553B (enExample)
AU (1) AU2012217836B2 (enExample)
CA (1) CA2826714C (enExample)
DK (3) DK4233537T3 (enExample)
ES (3) ES3040596T3 (enExample)
FI (2) FI4233537T3 (enExample)
IL (7) IL227704A0 (enExample)
MX (3) MX338971B (enExample)
MY (1) MY162984A (enExample)
PT (3) PT2675271T (enExample)
RU (2) RU2577978C2 (enExample)
SG (3) SG192606A1 (enExample)
WO (1) WO2012112544A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002988A1 (en) 2009-07-01 2011-01-06 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (scid)
EP3417701B1 (en) 2009-10-06 2021-12-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
RU2577978C2 (ru) 2011-02-15 2016-03-20 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
RU2751240C2 (ru) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
NZ746089A (en) 2012-09-07 2020-05-29 Institute For Res In Biomedicine Irb Genetically modified non-human animals and methods of use thereof
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
JP6475172B2 (ja) 2013-02-20 2019-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットの遺伝子組換え
CN103409468B (zh) * 2013-03-20 2015-08-12 中国科学院广州生物医药与健康研究院 一种免疫缺陷小鼠模型的建立方法
EP3456831B1 (en) 2013-04-16 2021-07-14 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
EP3461811A1 (en) 2013-06-17 2019-04-03 3M Innovative Properties Co. Process for preparing guanidino-functional monomers
SMT202500280T1 (it) 2013-09-23 2025-09-12 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
TR201904342T4 (tr) 2013-10-15 2019-05-21 Regeneron Pharma Hümani̇ze il-15 hayvanlar
EP3071024B1 (en) * 2013-11-19 2018-09-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
EP3430898A1 (en) * 2013-11-19 2019-01-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
BR112016026245A2 (pt) * 2014-05-30 2018-02-20 Regeneron Pharma ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor?
ES2969389T3 (es) 2014-12-05 2024-05-17 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
EP4399969A3 (en) * 2014-12-09 2024-10-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
SG10202103445QA (en) 2015-04-13 2021-05-28 Regeneron Pharma Humanized sirpa-il15 knockin mice and methods of use thereof
CN105994125B (zh) * 2015-04-15 2019-05-17 中国科学院广州生物医药与健康研究院 一种评价免疫缺陷小鼠模型的免疫缺陷程度的方法
US20180289840A1 (en) * 2015-05-24 2018-10-11 Central Institute For Experimental Animals Method for Evaluating Hematological Toxicity of Drug Under Evaluation, and Model for Evaluating Hematological Toxicity of Drug Under Evaluation
TWI810145B (zh) 2015-06-23 2023-08-01 杰克森實驗室 具有病患衍生之異種移植物之非ｈｌａ配對的人源化ｎｓｇ小鼠模式
CN105145486A (zh) * 2015-07-22 2015-12-16 中国医学科学院医学实验动物研究所 Rag2基因敲除大鼠在建立个性化肿瘤治疗模型中的应用
PT3376857T (pt) 2015-11-20 2021-05-27 Regeneron Pharma Animais não humanos com um gene humanizado 3 de ativação de linfócitos
US10582702B2 (en) 2016-02-04 2020-03-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered ANGPTL8 gene
KR101887051B1 (ko) * 2016-02-12 2018-08-10 한국과학기술원 오브젝트 탐닉행동을 활용한 동물행동 조절 방법
CA3014645C (en) 2016-02-29 2022-10-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
JP7458185B2 (ja) 2016-11-30 2024-03-29 ザ ジャクソン ラボラトリー 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル
EP4361637A3 (en) 2017-04-17 2024-07-17 The Jackson Laboratory Method of determining toxicity of an immunomodulatory drug for use in humans
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
HUE067361T2 (hu) 2018-07-16 2024-10-28 Regeneron Pharma Ditra betegség rágcsáló modelljei és alkalmazásaik
WO2020041174A1 (en) * 2018-08-20 2020-02-27 The Jackson Laboratory Method of determining toxicity of an immunomodulatory drug
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
AU2020253532B2 (en) 2019-04-04 2024-06-20 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
SG11202111256XA (en) 2019-06-07 2021-11-29 Regeneron Pharma Non-human animals comprising a humanized albumin locus
WO2021011853A2 (en) * 2019-07-17 2021-01-21 Yale University Genetically modified non-human animals and methods of use thereof
CN114829882B (zh) 2019-11-05 2023-02-28 阿比尔技术公司 植物产品中感染的预测
JP2023511626A (ja) * 2020-01-28 2023-03-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｐｎｐｌａ３遺伝子座を含む非ヒト動物および使用方法
JP2023542539A (ja) 2020-09-24 2023-10-10 ザ ジャクソン ラボラトリー 免疫細胞療法を評価するためのヒト化マウスモデル
CN113100175B (zh) * 2021-03-08 2022-07-12 北京大学人民医院 一种巨细胞病毒感染的人源化小鼠模型及其构建方法
CN114853871B (zh) * 2021-04-20 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Csf1和/或csf1r基因人源化的非人动物及其构建方法和应用
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030028911A1 (en) * 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) * 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
HU215241B (hu) 1986-10-24 1998-11-30 Cetus Corp. Eljárás telepstimuláló faktor-1 új formáinak előállítására, valamint az eljárásban alkalmazható expressziós kazetta, vektor és rekombináns gazdasejtek előállítására
ES2071620T3 (es) 1987-12-23 1995-07-01 Univ Leland Stanford Junior Mamiferos inmunodeficientes quimericos y su utilizacion.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
DE69131331T2 (de) 1990-01-15 2000-03-02 Yeda Research And Development Co., Ltd. Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DK0481058T3 (da) 1990-05-03 1996-12-02 Systemix Inc Humant, lymfatisk væv i en immunokompromitteret vært
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
JPH05500617A (ja) 1990-05-25 1993-02-12 システミックス，インコーポレイティド 免疫処理された宿主におけるヒト末梢血液細胞
CA2103705C (en) 1991-02-11 1996-01-30 Ayub K. Ommaya Spinal fluid driven artificial organ
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
WO1996003495A1 (en) 1994-07-27 1996-02-08 Merck & Co., Inc. Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
EP0973381B1 (en) 1997-04-09 2010-03-03 AMDL, Inc. Animal model for evaluation of vaccines
CA2382383A1 (en) * 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
JP2004500810A (ja) 1999-12-09 2004-01-15 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｉｌ−６様ポリヌクレオチド、ポリペプチド、および抗体
WO2002022786A1 (en) 2000-09-14 2002-03-21 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
JP4087338B2 (ja) 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
JPWO2004005496A1 (ja) 2002-07-05 2005-11-04 麒麟麦酒株式会社 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
AU2003278790A1 (en) 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1418185A1 (en) * 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
EP1573314B1 (en) 2002-12-16 2008-07-23 Genentech, Inc. Transgenic mice expressing human cd20
CN1751236A (zh) * 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
SI2019683T2 (sl) 2006-04-25 2022-10-28 The Regents Of The University Of California Dajanje rastnih faktorjev za zdravljenje motenj CŽS
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
WO2008069659A1 (en) 2006-12-05 2008-06-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
CA2687688C (en) * 2007-05-23 2017-03-28 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression in t cells
GB0718029D0 (en) * 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
US20110118446A1 (en) 2007-09-28 2011-05-19 The General Hospital Corporation Methods and compositions for antibody production
EP2257250A2 (en) 2008-01-29 2010-12-08 Gilbert H. Kliman Drug delivery devices, kits and methods therefor
AU2013204613A1 (en) 2008-12-24 2013-05-16 The Kingdom of The Netherlands, Represented by The Minister of Health, Welfare and Sport Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
CN102725400A (zh) 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
JP2012531894A (ja) 2009-06-29 2012-12-13 レスコフ，イリヤ，ビー． ヒト血液癌の非ヒト哺乳動物モデル
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
EP3417701B1 (en) 2009-10-06 2021-12-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
EP2618656B1 (en) 2010-09-20 2018-06-20 Yale University, Inc. HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
RU2577978C2 (ru) 2011-02-15 2016-03-20 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
RU2751240C2 (ru) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
NZ746089A (en) 2012-09-07 2020-05-29 Institute For Res In Biomedicine Irb Genetically modified non-human animals and methods of use thereof
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
SMT202500280T1 (it) 2013-09-23 2025-09-12 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
TR201904342T4 (tr) 2013-10-15 2019-05-21 Regeneron Pharma Hümani̇ze il-15 hayvanlar
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
SG10202103445QA (en) 2015-04-13 2021-05-28 Regeneron Pharma Humanized sirpa-il15 knockin mice and methods of use thereof
AU2017290710A1 (en) 2016-06-29 2019-01-24 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat a variety of pruritic conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030028911A1 (en) * 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity

Also Published As

Publication number Publication date
IL253743B (en) 2019-05-30
DK3375284T3 (da) 2023-06-12
NZ613948A (en) 2015-06-26
CN111808879A (zh) 2020-10-23
JP5834097B2 (ja) 2015-12-16
KR102256316B1 (ko) 2021-05-28
JP6505786B2 (ja) 2019-04-24
FI3375284T3 (fi) 2023-06-15
US20130042330A1 (en) 2013-02-14
EP2675271B1 (en) 2018-06-13
JP2014510520A (ja) 2014-05-01
KR102390850B1 (ko) 2022-04-26
IL253743A0 (en) 2017-09-28
WO2012112544A3 (en) 2012-11-15
MY162984A (en) 2017-07-31
IL239350A (en) 2017-12-31
CN111808879B (zh) 2024-12-31
CN103547148B (zh) 2016-06-08
RU2016104468A (ru) 2018-11-22
US20210112791A1 (en) 2021-04-22
MX380588B (es) 2025-03-12
CA2826714C (en) 2022-11-08
RU2577978C2 (ru) 2016-03-20
DK4233537T3 (da) 2025-08-25
EP2675271A4 (en) 2015-03-18
IL227704A0 (en) 2013-09-30
KR20230145500A (ko) 2023-10-17
RU2020126649A (ru) 2022-02-10
KR20200003241A (ko) 2020-01-08
CA2826714A1 (en) 2012-08-23
KR20200054323A (ko) 2020-05-19
JP2019122397A (ja) 2019-07-25
IL238781A (en) 2017-08-31
SG192606A1 (en) 2013-09-30
IL239350A0 (en) 2015-07-30
EP3375284A1 (en) 2018-09-19
JP6188765B2 (ja) 2017-08-30
NZ708040A (en) 2016-10-28
JP6732987B2 (ja) 2020-07-29
MX2013009406A (es) 2013-12-16
JP2017189180A (ja) 2017-10-19
US12127536B2 (en) 2024-10-29
RU2013142043A (ru) 2015-03-27
AU2012217836A1 (en) 2013-03-28
RU2730643C2 (ru) 2020-08-24
KR20210062718A (ko) 2021-05-31
US9655352B2 (en) 2017-05-23
RU2016104468A3 (enExample) 2019-06-26
IL278385B (en) 2021-12-01
EP4233537B1 (en) 2025-07-09
JP7181911B2 (ja) 2022-12-01
IL266886B (en) 2020-11-30
US10785966B2 (en) 2020-09-29
PT4233537T (pt) 2025-09-08
KR20140020865A (ko) 2014-02-19
SG10201601067WA (en) 2016-03-30
JP2020168023A (ja) 2020-10-15
DK2675271T3 (en) 2018-08-27
CN105861553A (zh) 2016-08-17
KR102585058B1 (ko) 2023-10-05
PT3375284T (pt) 2023-06-28
US20150047061A1 (en) 2015-02-12
IL266886A (en) 2019-07-31
JP2016039818A (ja) 2016-03-24
ES2948210T3 (es) 2023-09-06
ES3040596T3 (en) 2025-11-03
SG10202008003VA (en) 2020-10-29
EP4233537A3 (en) 2023-09-13
FI4233537T3 (fi) 2025-08-27
IL238781A0 (en) 2015-06-30
MX338971B (es) 2016-05-06
WO2012112544A2 (en) 2012-08-23
KR102714361B1 (ko) 2024-10-11
US20250072406A1 (en) 2025-03-06
NZ724014A (en) 2018-12-21
CN105861553B (zh) 2020-08-14
IL288167A (en) 2022-01-01
KR102109172B1 (ko) 2020-05-12
US8847004B2 (en) 2014-09-30
EP3375284B1 (en) 2023-03-29
US20170273285A1 (en) 2017-09-28
ES2685790T3 (es) 2018-10-11
KR20220054718A (ko) 2022-05-03
PT2675271T (pt) 2018-10-11
MX350385B (es) 2017-09-04
EP4233537A2 (en) 2023-08-30
CN103547148A (zh) 2014-01-29
KR102061143B1 (ko) 2019-12-31
EP2675271A2 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
US20250072406A1 (en) Humanized M-CSF Mice
AU2018213980B2 (en) Humanized M-CSF mice
HK40098113A (en) Humanized m-csf mice and uses thereof
HK40098113B (en) Humanized m-csf mice and uses thereof
AU2015202020B2 (en) Humanized M-CSF mice
NZ724014B2 (en) Humanized m-csf mice
HK1191804B (en) Humanized m-csf mice
HK1191804A (en) Humanized m-csf mice
NZ613948B2 (en) Humanized m-csf mice
NZ708040B2 (en) Humanized m-csf mice

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ: MURPHY, ANDREW J.; STEVENS,SEAN; RATHINAM, CHOZHAVENDAN; EYNON, ELIZABETH; MANZ, MARKUS; FLAVELL, RICHARD AND YANCOPOULOS, GEORGE D.

FGA Letters patent sealed or granted (standard patent)